Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies

Table 1 Demographic and clinical findings in patients with systemic lupus erythematosus grouped according to their psychiatric symptoms

Characteristic	Group A^a (n = 17)	Group B^a (n = 34)
Age (years) (mean, range)	37, 23–52	36.7, 14–70
Sex (males/females)	3/14	4/30
Disease duration (years) (mean, range)	9.6, 0.5–21	10, 0.5–24
SLEDAI (mean ± SD)	5.0 ± 5.5	5.1 ± 7.5
Neurological manifestations [no. (%)]	5 (29.4)	13 (38.2)
Cutaneous manifestations [no. (%)]	13 (76.5)	21 (61.8)
Arthritis [no. (%)]	14 (82.3)	23 (67.6)
Renal manifestations [no. (%)]	2 (11.8)	12 (35.3)
Cytopenia [no. (%)]	12 (70.6)	20 (58.8)
Serositis [no. (%)]	4 (23.5)	10 (29.4)
Prednisone [no. (%); mean mg/day]	12 (70.6); 10.0	28 (82.3); 12.3
Hydroxychloroquine [no. (%)]	5 (29.4)	16 (47)
Azathioprine [no. (%)]	4 (23.5)	8 (23.5)
Methotrexate [no. (%)]	2 (11.8)	2 (5.9)
Cyclosporin A [no. (%)]	3 (17.6)	4 (11.8)
Cyclophosphamide [no. (%)]	none	3 (8.8)

^aGroup A, patients with mood disorders and psychosis; group B, patients without psychiatric manifestations other than anxiety. Differences between the groups as measured by the chi-squared or Wilcoxon unpaired tests were not statistically significant. SLEDAI, systemic lupus erythematosus Disease Activity Index.

ISSN: 1478-6362